In what is normally a slow–growing category in the 0.5%-3.0% range for year–over–year performance, the internal analgesics category witnessed much stronger–than–average growth rates in 2020. Consumers stocked up on pain relievers and fever reducers to be prepared for coronavirus. The overall internal analgesics category witnessed sales growth of more than 6.0%, with the Tylenol brand up nearly 40% and Motrin IB (both by Johnson & Johnson) up nearly 100% compared to 2019 sales. Continue reading
In 2020, the U.S. market saw four new brands previously sold as prescription drugs enter the nonprescription market:
- Pataday allergy eye drops
- Voltaren Arthritis Pain topical NSAID
- Advil Dual Action ibuprofen and acetaminophen pain reliever
- Sklice lice treatment
The new switch approvals have signaled a willingness on the part of regulators to be less conservative when it comes to OTC access to these medicines. Nasal steroid switches, like Flonase and Rhinocort, along with the topical NSAID Voltaren Arthritis Pain and Sklice lice shampoo, are all in categories where switch activity was curtailed in the not-so-distant past due to concerns over systemic absorption of topically applied medicines. For in-depth profiles of recently approved FDA switches, subscribe to the all-new KlinePULSE Consumer Healthcare Industry Trends service. Continue reading
As 2020 concludes, we are reflecting on the priority of health and safety, and how drastically different our everyday lives are compared to just eight months ago. We have seen major shifts toward the importance of immunity, with less emphasis on treatment of symptoms and more focus on prevention. We have a new perspective on the evolving role consumer healthcare products play in keeping us healthy. To help you put these major trends into perspective, below is a summary of our market studies and whitepapers that were published throughout the year. Continue reading
During 2020, virtually every industry and every aspect of how we live, work, and communicate was thrown into disarray due to the COVID-19 pandemic. The necessity to respond to the global crisis with tech-savvy, relevant, and timely solutions was a catalyst that sparked the rapid development and implementation of evolutionary trends on a scale we’ve never seen before.
With 2020 almost over, we want to part with it on a positive note by reflecting on these progressive, dynamic trends and how they will come together to help us “rebuild better” post-COVID-19.Continue reading
The U.S. FDA approved five new branded Rx-to-OTC switches in 2020, including eye drops, an external analgesic, and a lice treatment. In addition, private-label companies such as Perrigo and Mylan gained approval for store brand versions of Voltaren Arthritis Pain Gel, Prevacid 24HR proton pump inhibitor, and Nicorette smoking cessation gum this year. These approvals come after a lull in switch activity during the past two years. Continue reading
Recently, in Europe and Japan there have been increased Rx-to-OTC switch approvals and an environment fostering switch. The OTC men’s health category is growing in Europe, with the switch approval of Recordati’s Fortacin (lidocaine 7.5mg/prilocaine 2.5 mg) spray for premature ejaculation, via the centralized switch procedure through the European Medicines Agency. This drug marks the fifth medicine approved for switch through this centralized regulatory body, and it is expected to be launched throughout the EU on a nonprescription basis by early 2021.
Overall, the U.S. market for nutritional supplements is up nearly 15% so far in 2020 as consumers seek to protect their health with immune-enhancing products. All segments of the market increased by double-digit growth rates, with particularly high gains for vitamins A, B12, C, D, iron, magnesium, zinc, echinacea, and elderberry. Continue reading
American consumers are increasingly using personalized subscription services for clothing, beauty products, and meal kits—plus vitamins and nutritional supplements. In a category worth more than $10 billion—with as much as 75% of the population regularly consuming supplements—the sheer number of available products and brands can be confusing. That’s why personalization makes sense, as it helps consumers navigate a somewhat perplexing category. Continue reading
After years of the OTC industry and the Consumer Healthcare Products Association working with the FDA to pass long-overdue OTC monograph reform and regulatory modernization, long-sought-after reform is now a reality thanks to the CARES (Coronavirus Aid, Relief, and Economic Security) Act. The act, which was passed by the U.S. Congress and signed into law by President Donald Trump on March 27, 2020, provides more than $110 million over five years for the FDA to significantly increase capacity and expertise in the Office of Nonprescription Drug Products. Continue reading
Across the United States, cannabidiol (CBD) has emerged as a prominent ingredient used in the healthcare, beauty, and food & beverages industries. Owing to the passage of the 2018 United States Farm Bill, which legalized the cultivation, sale, and distribution of hemp, consumer attitudes and usage of CBD enhanced over the past two years.
Considering cannabis-infused food and beverages, the overall market achieved strong double-digit growth of over 70% in 2019. Meanwhile, the market for CBD health and wellness products is forecast to reach nearly $2 billion by 2024 with steady growth every year. In the beauty industry, CBD remains the “it” ingredient that can be found in everything from skin care products to makeup and hair care.